

Indian Journal of Dermatology, Venereology & Leprology

CONTENTS

<p>Editor Uday Khopkar</p> <p>Associate Editors Ameet Valia Sangeeta Amladi</p> <p>EDITORIAL BOARD MEMBERS Sandipan Dhar Sanjeev Handa H. R. Jerajani Sharad Mutalik C. M. Oberai M. Ramam D. A. Satish Rajeev Sharma Shruthakirti Shenoj C. R. Srinivas D. M. Thappa S. L. Wadhwa</p> <p>Ex-officio Members A. K. Bajaj S. Sacchidanand</p> <p>EDITORIAL OFFICE Dr. Uday Khopkar Editor, IJDVL 2/7, Govt. Colony, Haji Ali, Mumbai-400034. E-mail: editor@ijdv.com</p> <p>PUBLISHED BY Medknow Publications 12, Manisha Plaza, M. N. Road, Kurla (W), Mumbai-400070, India. Phone: 91-22-25032970 Fax: 91-22-25032398 E-mail: publishing@medknow.com Website: www.medknow.com</p> <p>Manuscript submission www.journalonweb.com/ijdv</p> <p>Cover design courtesy Sudler & Hennessey</p>	<p>EDITORIAL</p> <p>PRESIDENTIAL ADDRESS</p> <p>REVIEW ARTICLE</p> <p>STUDIES</p> <p>CASE REPORTS</p>	<p>IJDVL at the crossroads</p> <p>A. K. Bajaj</p> <p>Serious cutaneous adverse drug reactions: Pathomechanisms and their implications to treatment Arun C. Inamdar, Aparna Palit</p> <p>Diltiazem vs. nifedipine in chilblains: A clinical trial A. K. Patra, A. L. Das, P. Ramadasan</p> <p>A comparative study of PUVASOL therapy in lichen planus Lata Sharma, M. K. Mishra</p> <p>Utility of polymerase chain reaction as a diagnostic tool in cutaneous tuberculosis Padmavathy L., Lakshmana Rao L., Veliath A. J.</p> <p>Therapeutic efficacy of intralesional triamcinolone acetonide versus intralesional triamcinolone acetonide plus lincomycin in the treatment of nodulocystic acne B. B. Mahajan, Geeta Garg</p> <p>Ichthyosiform sarcoidosis following chemotherapy of Hodgkin's disease M. P. S. Sawhney, Y. K. Sharma, V. Gera, S. Jetley</p> <p>Urticarial vasculitis in infancy Sukhjot Kaur, Gurvinder P. Thami</p> <p>Koebner phenomenon in PLEVA Arun C. Inamdar, Aparna Palit</p> <p>Familial acrogeria in a brother and sister Shaikh Manzoor Ahmad, Imran Majeed</p> <p>Cornelia de Lange syndrome K. Muhammed, B. Safia</p>	<p>_____ 203</p> <p>_____ 204</p> <p>_____ 205</p> <p>_____ 209</p> <p>_____ 212</p> <p>_____ 214</p> <p>_____ 217</p> <p>_____ 220</p> <p>_____ 223</p> <p>_____ 225</p> <p>_____ 227</p> <p>_____ 229</p>
---	--	---	---

Indian Journal of Dermatology, Venereology & Leprology

CONTENTS (CONTD.)

The Indian Journal of Dermatology, Venereology and Leprology is a bimonthly publication of the Indian Association of Dermatologists, Venereologists and Leprologists and published by Medknow Publications.

The Journal is indexed/listed with Health and Wellness Research Center, Health Reference Center Academic, InfoTrac One File, Expanded Academic ASAP, NIWI, INIST, Uncover, JADE (Journal Article Database), IndMed, Indian Science Abstract's and PubList.

All the rights are reserved. Apart from any fair dealing for the purposes of research or private study, or criticism or review, no part of the publication can be reproduced, stored, or transmitted, in any form or by any means, without the prior permission of the Editor, Indian Journal of Dermatology, Venereology and Leprology.

The information and opinions presented in the Journal reflect the views of the authors and not of the Indian Journal of Dermatology, Venereology and Leprology or the Editorial Board or the Indian Association of Dermatologists, Venereologists and Leprologists. Publication does not constitute endorsement by the journal.

The Indian Journal of Dermatology, Venereology and Leprology and/or its publisher cannot be held responsible for errors or for any consequences arising from the use of the information contained in this journal. The appearance of advertising or product information in the various sections in the journal does not constitute an endorsement or approval by the journal and/or its publisher of the quality or value of the said product or of claims made for it by its manufacturer.

For advertisements, please contact the Editor

	Intralesional steroid induced histological changes in the skin	
	Sukhjot Kaur, Amanjeet, Gurvinder P. Thami, Harsh Mohan	232
	Sparfloxacin induced toxic epidermal necrolysis	
	M. Ramesh, G. Parthasarathi, B. Mohan, A. B. Harugeri	235
	Fever due to levamisole	
	Ramji Gupta, Sameer Gupta	237
	Localized cutaneous sporotrichosis lasting for 10 years	
	Sanjay K. Rathi, M. Ramam, C. Rajendran	239
QUIZ	S. V. Rakesh, D. M. Thappa	241
RESIDENT'S PAGE	Sign of Nikolskiy & related signs	
	Deepa Sachdev	243
RESEARCH METHODOLOGY	Declaration of Helsinki: The ethical cornerstone of human clinical research	
	Gulrez Tyebkhan	245
MEDICOLEGAL WINDOW	Drug eruptions and drug reactions	
	Subodh P. Sirur	248
LETTERS TO EDITOR	Aggravation of preexisting dermatosis with <i>Aloe vera</i>	250
	Familial woolly hair in three generations	250
	Chronic pelvic inflammatory disease and melasma in women	251
	Comments on "Serological study for sexually transmitted diseases in patients attending STD clinics in Calcutta"	252
BOOK REVIEW	Colour atlas and synopsis of paediatric dermatology	
	Sandipan Dhar	255
ANNOUNCEMENTS		255, 256,
INSTRUCTIONS TO AUTHORS		258

Sparfloxacin induced toxic epidermal necrolysis

M. Ramesh, G. Parthasarathi, B. Mohan,* A. B. Harugeri

Department of Clinical Pharmacy, J. S. S. Medical College Hospital, Mysore, India and Department of *Medicine, Holdsworth Memorial Hospital, Mysore, India.

Address for correspondence: Mr. M. Ramesh, Department of Pharmacy Practice, J. S. S. College of Pharmacy, S.S. Nagar, Mysore-15, India. E-mail: madhanramesh@hotmail.com

ABSTRACT

Toxic epidermal necrolysis (TEN) is a life-threatening cutaneous adverse drug reaction. TEN is known to occur with the fluoroquinolone class of antibiotics, but only four cases of sparfloxacin induced TEN have been reported to the WHO database. This is another case report of sparfloxacin induced TEN.

KEY WORDS: Adverse drug reaction, Fluoroquinolones, Sparfloxacin, Toxic epidermal necrolysis

INTRODUCTION

TEN is known to occur with the fluoroquinolones. However, the incidence of sparfloxacin induced TEN is very low, with only four cases having been reported to the WHO database.¹ We report here one more case.

CASE REPORT

A 17-year-old boy with a three-day history of cough and fever was treated with sparfloxacin 400 mg on day one and 200 mg on the following two days. On day three of treatment the patient was hospitalized at our centre for an extensive blistering rash and involvement of the eyes, oral and nasal mucosa. He had greater than 60% cutaneous detachment and was diagnosed as drug induced toxic epidermal necrolysis (TEN). Except for electrolyte imbalance, all the hematological tests and liver and renal functions were within normal limits.

Sparfloxacin was stopped and the patient was treated with injections of pheniramine maleate and methyl prednisolone 1 g o.d. intravenously for 4 days. The oral mucosa was treated with metronidazole 1% gel and

chlorhexidine mouth wash. Oral prednisolone 40 mg o.d. was begun on the fifth day of admission and was continued until day 19, with constant monitoring of the patient's condition in an intensive care area. Based on culture sensitivity reports, he was treated with various injectable antibiotics during his hospital stay. These included amoxicillin + sulbactam 1.5 g b.i.d., ceftriaxone 1 g b.i.d., cefoperazone 1 g b.i.d. and gentamicin 120 mg o.d. on different days. During this period he was gradually improving, but on the day 22 of hospitalization, he died of suspected pulmonary emboli.

The causality assessment of the reaction was 'probable' by both the WHO probability scale and Naranjo's ADR probability scale.

DISCUSSION

The number of hospital admissions related to TEN is reported to be 0.5 per million per year² with a mortality rate between 20% and 66% in the acute phase. The medications most frequently reported to precipitate TEN include sulfonamides, phenytoin, allopurinol,

carbamazepine, non-steroidal anti-inflammatory drugs, antibacterials and barbiturates.^{3,4} Non-drug etiologies are uncommon but include viral, bacterial and fungal infections and neoplastic diseases.⁵ Early withdrawal of the causative drug with a half life less than 24 hours is associated with a better prognosis and a lower mortality.³ Sparfloxacin has a half life of 16 hrs. Prompt withdrawal of sparfloxacin in the case of TEN may decrease the mortality.

Corticosteroids are used in the treatment of TEN in an attempt to impede the basic pathophysiology, by inhibiting antibody-dependent cytotoxicity. The use of corticosteroids in the management of TEN has fallen into disfavor because of an increased incidence of sepsis, a five-fold increase in the incidence of infection if used for more than 48 hours, a longer hospital stay and an increased mortality rate.⁵⁻⁸ Though intravenous immunoglobulin therapy is a promising experimental treatment,^{9,10} more trials are needed before it is adopted as the treatment of choice.

ACKNOWLEDGEMENTS

The authors would like to thank the administrative staff, chief pharmacist, medical practitioners and nursing staff of Holdsworth Memorial Hospital, Mysore for their cooperation in this publication. We also extend our thanks to JSS Mahavidyapeeta and Principal, JSS College of Pharmacy, Mysore for their support.

REFERENCES

1. Personal communication with Erica Walette, Database services, Uppsala Monitoring Centre, Stora Torgets S – 753 20 Uppsala, Sweden.
2. Chan HI, Stern RS, Arndt KA, Langlois J, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. *Arch Dermatol* 1990;126:43-7.
3. Garcia-Doval I, Leclach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: Does early withdrawal of causative drugs decrease the risk of death? *Arch Dermatol* 2000;136:323-7.
4. Guillame JC, Roujeau JC, Revvuz J, et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell syndrome). *Arch Dermatol* 1987;123:1160-70.
5. Kalem J III, Cioffi WG, McManus WF, Mason AD, et al. Burn center care for patients with toxic epidermal necrolysis. *J Am Coll Surg* 1995;180:273-8.
6. Toxic epidermal necrolysis: A systemic and metabolic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids (editorial). *J Am Coll Surg* 1995;180:340-2.
7. Improving the outcome of patients with toxic epidermal necrolysis and Stevens-Johnson syndrome (Editorial). *Arch Dermatol* 2000;136:410-1.
8. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. *Ann Surg* 1986;204:503-12.
9. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. *Science* 1998;282:490-3.
10. Magina S, Lisboa C, Goncalves E, et al. A case of toxic epidermal necrolysis treated with intravenous immunoglobulin. *Br J Dermatol* 2000;142:191-2.